Stem-cell MS Treatment May Not Erase Certain Old Lesions

Credibility

Interest

Key Takeaway

A powerful stem-cell–based MS treatment did not make chronic 'paramagnetic rim' brain lesions go away within about a year after transplant.

What They Found

Researchers looked at special high-resolution 7T MRI scans from seven people with MS before and after they had autologous hematopoietic cell transplantation (AutoHCT), a procedure that resets the immune system. They counted paramagnetic rim lesions (PRLs) — a type of long-lasting lesion that often marks ongoing inflammation — and found a median of two PRLs per person before transplant. About 15 months after the transplant (in five people who had follow-up scans), none of those PRLs disappeared. In other words, while AutoHCT is known to reduce new lesion activity, it did not remove these specific chronic lesions in this small group. The study suggests PRLs may be stubborn, lasting signs of past or ongoing damage that a single transplant may not reverse quickly.

Who Should Care and Why

People with MS and caregivers should care because PRLs are linked to long-term progression; knowing they may not disappear after AutoHCT helps set realistic expectations. If you’re considering or have had AutoHCT, understand that the treatment can lower new disease activity but might not erase older, chronic lesions that show a rim on special MRIs. Neurologists and MS care teams can use this information when discussing goals of treatment — like preventing new damage versus repairing old damage — similar to how a roof repair prevents new leaks but doesn’t fix water stains already on the ceiling. Caregivers should focus on symptom management and rehabilitation after transplant, since some visible MRI changes may persist even if new attacks stop. This helps prioritize monitoring, physical therapy, and symptom-targeted care rather than expecting all MRI findings to normalize quickly.

Important Considerations

This study was very small (only seven people) and used one rater to count lesions, so the results are preliminary and could change with larger studies. Follow-up time was limited (about 15 months for most), so PRLs might take longer to change than the study allowed; we can’t say they never resolve. Because this is low-level evidence, people should not use it alone to make big treatment decisions — discuss with your MS doctor who can place these findings into the context of your overall care.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics Clinical Trials Early Research

Article Topics:

MRIMultiple sclerosishematopoietic cell transplantationparamagnetic rim lesionsprogressive

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Multiple sclerosis (Houndmills, Basingstoke, England) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News